Research suggests NAC is capable of enhancing T-cell immunity by stimulating T-cell colony formation, and blocking NF kappa B expression. In a double-blind, placebo-controlled trial, NAC was shown to positively impact CD4+ lymphocyte cell counts. NAC has application for respiratory ailments due to its mucolytic activity. NAC’s sulfhydryl group cleaves disulfide bonds in mucoproteins, causing mucus to be subsequently broken into smaller, less viscous units. NAC has been noted to decrease the viscoelasticity of nasal mucus and increase the mucociliary clearance rate by thinning of secretions, improving conditions such as bronchitis and flu. Several animal and human studies have explored NAC’s effectiveness as a therapeutic agent for various types of respiratory illness. While results vary, NAC administration has resulted in improved expectoration, with decreased cough severity and diaphragm fatigue. In a small study of 18 patients with fibrosing alveolitis – a condition characterized by severe oxidative stress and decreased glutathione levels – NAC 600 mg three times daily for 12 weeks resulted in improvement in pulmonary function and glutathione levels.
|Supplement Facts||Dosage:1 capsule tid with meals
A woman who is pregnant or nursing, or who might become pregnant, should consult a health-care practitioner before using this product.
|Name||Thorne Research, CystePlus 500 mg 90 capsules|
|Product Type||Corn Free, Dairy Free, Egg Free, Gluten Free, Hypoallergenic, Wheat Free, Yeast Free|